-
London, Ontario–headquartered EpiSign is revolutionizing rare disease diagnostics through AI
Across global healthcare systems, millions of patients remain stuck in what clinicians call the ‘diagnostic odyssey’—years of testing, referrals, and unanswered questions, especially for patients with rare genetic disorders. According to CARE4RARE Canada (formed under Finding Rare Disease Genes in Canada), fewer than one-third of patients with suspected rare genetic conditions ever receive a definitive diagnosis. These delays not only affect patients and families, but they also postpone appropriate treatment, drive up healthcare costs, and place sustained strain on overburdened health systems.
That gap between data and diagnosis is one of the most critical challenges in modern medicine and it’s exactly where EpiSign Inc., a London, Ontario–headquartered Canadian biotechnology company, is making a global impact.
Developed at the intersection of artificial intelligence, cloud computing, and epigenetics, this innovative companyis redefining how rare diseases are detected, and in doing so, further amplifies London as a global hub for AI-enabled health diagnostics.
Read full article here: https://canadiansme.ca/london-ontario-headquartered-episign-is-revolutionizing-rare-disease-diagnostics-through-ai/
